20
Participants
Start Date
January 23, 2023
Primary Completion Date
February 23, 2028
Study Completion Date
February 23, 2028
Tolvaptan Suspension
Syrup
Tolvaptan Tablets
Tolvaptan (OPC-41061) Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets.
RECRUITING
Université Catholique De Louvain And Cliniques St Luc, Brussels
RECRUITING
UZ Leuven, Leuven
RECRUITING
Hospital Universitari Vall D Hebron, Barcelona
RECRUITING
Universitat de Barcelona - Hospital Sant Joan de Deu Barcelona (HSJDB), Esplugues de Llobregat
RECRUITING
Universitair Ziekenhuis Gent, Ghent
WITHDRAWN
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
RECRUITING
Children's National Medical Center, Washington D.C.
RECRUITING
Johns Hopkins Pediatric Specialty Clinic, Baltimore
NOT_YET_RECRUITING
Emory University Hospital, Atlanta
WITHDRAWN
Hospital Universitario Virgen del Rocío Avenida Manuel Siurot, Seville
RECRUITING
Cleveland Clinic, Cleveland
RECRUITING
Universitätsklinikum Köln, Cologne
RECRUITING
Mayo Clinic - Rochester, Rochester
RECRUITING
Northwestern University Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago - Neonatology, Chicago
WITHDRAWN
Children's Hospital - New Orleans, New Orleans
WITHDRAWN
Primary Children's Hospital, Salt Lake City
WITHDRAWN
Riley Hospital for Children, Indianapolis
RECRUITING
C.S. Mott Children's Hospital, Ann Arbor
RECRUITING
Cincinnati Children's Hospital Medical Center, Cincinnati
WITHDRAWN
"Instytut Pomnik - Centrum Zdrowia Dziecka", Warsaw
WITHDRAWN
Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa, Bialystok
WITHDRAWN
Hospital Universitari Parc Tauli, Sabadell
RECRUITING
Great Ormond Street Hospital for Children NHS Trust, London
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY